Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.48 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.48 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.48 |
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP1 | P63208 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296681 | 0.86 | POLB (0.46) | GBA1MEN1KMT2APOLBKIT | |
| SCHEMBL29517425 | 0.86 | POLB (0.46) | GBA1MEN1KMT2APOLBKIT | |
| SCHEMBL21221762 | 0.84 | SMO (0.66) | MEN1KMT2APOLBCKS1BSKP1 | |
| SCHEMBL12786109 | 0.84 | KMT2A (0.70) | MEN1KMT2AGFERPOLBADRB2 | |
| SCHEMBL29552372 | 0.83 | KMT2A (0.55) | GBA1MEN1KMT2APOLBKIT | |
| SCHEMBL1102296 | 0.83 | SMO (0.52) | SMARCA2SMARCA4PBRM1SMO | |
| SCHEMBL2276473 | 0.83 | SMO (0.52) | SMARCA2SMARCA4PBRM1SMO | |
| SCHEMBL2276478 | 0.83 | SMO (0.52) | SMARCA2SMARCA4PBRM1SMO | |
| SCHEMBL1102299 | 0.82 | SMO (0.51) | MEN1KMT2AGFERGPR119SMO | |
| SCHEMBL4166702 | 0.82 | SMO (0.51) | MEN1KMT2AGFERGPR119SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882717-B1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-6750218-B2 | INHIBITORY ACTIVITY ON PHOSPHORYLATION OF PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | MILLENNIUMIUM PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | MATSUNO KENJI (JP) | 2003-12-11 | — | — | US | disclosed |
| US-6472391-B2 | INHIBIT PHOSPHORYLATION OF PDGF RECEPTOR TO HINDER ABNORMAL CELL GROWTH AND CELL WANDERING; TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6207667-B1 | USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | ERBB4, NPR1, PDGFRB | GBA1 3789/4885MEN1 4594/4885KMT2A 4539/4885 |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | GBA1 4122/4885MEN1 4677/4885KMT2A 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.